Daily Newsletter

27 November 2023

Daily Newsletter

27 November 2023

UK MHRA recalls batches of eye gels due to microbial contamination

People with eye infection symptoms should contact healthcare experts and inform them about the usage of recalled products.

Vishnu Priyan November 27 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued a recall of batches of carbomer-containing lubricating eye gels due to potential microbial contamination.

Eye gels containing carbomer provide relief from dry eye symptoms. 

The recalled gels are sold under the brand names Aacarb, Aacomer and Puroptics.

Issuing precautionary safety advice, the regulator warned patients to stop using the products and return them to their retailer.

Any user experiencing eye infection symptoms such as reduced vision or a red eye with pain should contact their healthcare provider.

Investigations are underway to ascertain if there are links between identified infections and usage of the recalled products.

MHRA Chief Safety Officer Alison Cave stated: “Whilst the risk to users is low, we are taking precautionary action.

“If you have been using these gels, and if your eye symptoms worsen or you are worried about your health, please contact your healthcare professional, and tell them you have been using an eye gel that has been recalled.

“Retailers should, where possible, contact patients who have been dispensed any of the affected batches and ask them to return the product.”

The UK Health Security Agency has recommended that people with cystic fibrosis, those who are severely immunocompromised, patients with specific risk factors and individuals awaiting lung transplants avoid usage of all carbomer-containing lubricating eye gels until further notice.

Why are healthcare companies hesitant to invest in the metaverse?

Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close